Cao Yanling 4
4 · Viela Bio, Inc. · Filed Mar 16, 2021
Insider Transaction Report
Form 4
Cao Yanling
Director10% Owner
Transactions
- Disposition to Issuer
Common Stock
2021-03-13$53.00/sh−8,322,353$441,084,709→ 0 total(indirect: Held by Boundless Meadow Limited)
Footnotes (2)
- [F1]Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger, each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price.
- [F2]Boundless Meadow Limited is wholly owned by Boyu Capital Fund III. L.P., which is a fund to which Boyu Capital Advisory Co. Limited provides non-discretionary investment advisory services. Mr. Cao is a Partner of Boyu Capital Advisory Co. Limited, and may be deemed to beneficially own the shares held by Boundless Meadow Limited. Mr. Cao disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any.